Although, FDG-PET studies have shown reduced glucose utilisation in the AD/MCI hypothalamus65, 66 studies with Aβ or tau tracers have not been forthcoming, potentially due to the small size of the hypothalamus, limiting spatial resolution, and off-target binding, which may increase the difficulty in assessing this brain region. This evidence concerns the gene MAPT and Alzheimer disease.